William Blair analyst Myles Minter has reiterated their bullish stance on TRDA stock, giving a Buy rating today.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Myles Minter’s rating is based on several promising developments within Entrada Therapeutics Inc. The company has made significant progress in its clinical trials, particularly with the initiation of the Phase I/II ELEVATE-44-201 trial for its dystrophin exon 44 skipper, ENTR-601-44, targeting Duchenne’s muscular dystrophy (DMD). This trial, which has already dosed its first patient, is expected to yield initial data in the first half of 2026, indicating a well-structured plan for advancing their therapeutic candidates.
Additionally, Entrada’s strategic focus on expanding its pipeline is evident with the planned initiation of a Phase Ib trial for the exon 44 skipper in the U.S. and the advancement of its retinal disease programs into lead optimization. These initiatives, coupled with the company’s ability to activate multiple clinical study sites and the anticipated dosing of the first patient for the exon 45 skipper study by the third quarter of 2025, highlight a robust pipeline and potential for future growth. Such strategic advancements and a clear roadmap for clinical development underpin Minter’s Buy rating for Entrada Therapeutics Inc.
Minter covers the Healthcare sector, focusing on stocks such as Moderna, Arcturus Therapeutics, and Axsome Therapeutics. According to TipRanks, Minter has an average return of 12.1% and a 53.60% success rate on recommended stocks.